Hauser SL, Bar-Or A, Cohen JA, et al. - In multiple sclerosis patients, researchers analyzed the relative effects of, ofatumumab, a subcutaneous anti-CD20 monoclonal antibody that selectively depletes B cells and teriflunomide, an oral inhibitor of pyrimidine synthesis that reduces T-cell and B-cell activation. Patients with relapsing multiple sclerosis were randomly assigned to receive subcutaneous ofatumumab (20 mg every 4 weeks after 20-mg loading doses at days 1, 7, and 14) or oral teriflunomide (14 mg daily) for up to 30 months in these two double-blind, double-dummy, phase 3 trials. There were 946 patients allocated to ofatumumab and 936 allocated to teriflunomide, who were followed-up over a median of 1.6 years. The authors concluded that ofatumumab was linked with lower annualized relapse rates vs among multiple sclerosis patients. Disability improvement confirmed at 6 months was 11.0% with ofatumumab and 8.1% with teriflunomide.